144 related articles for article (PubMed ID: 20383646)
21. Anti-proliferative effect of the kinase inhibitor K252a on human prostatic carcinoma cell lines.
Delsite R; Djakiew D
J Androl; 1996; 17(5):481-90. PubMed ID: 8957691
[TBL] [Abstract][Full Text] [Related]
22. Characterization of NCI-H295R cells as an in vitro model of hyperaldosteronism.
Lichtenauer UD; Shapiro I; Osswald A; Meurer S; Kulle A; Reincke M; Riepe F; Beuschlein F
Horm Metab Res; 2013 Feb; 45(2):124-9. PubMed ID: 23111829
[TBL] [Abstract][Full Text] [Related]
23. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V
Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271
[TBL] [Abstract][Full Text] [Related]
24. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.
Yde CW; Frogne T; Lykkesfeldt AE; Fichtner I; Issinger OG; Stenvang J
Cancer Lett; 2007 Oct; 256(2):229-37. PubMed ID: 17629615
[TBL] [Abstract][Full Text] [Related]
25. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
Leung KK; Shilton BH
Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells.
Götz C; Bachmann C; Montenarh M
Prostate; 2007 Feb; 67(2):125-34. PubMed ID: 17044081
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
Wang Y; An R; Dong X; Pan S; Duan G; Sun X
Urol Int; 2009; 82(2):214-21. PubMed ID: 19322013
[TBL] [Abstract][Full Text] [Related]
28. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
29. Secretion of cortisol and aldosterone as a vulnerable target for adrenal endocrine disruption - screening of 30 selected chemicals in the human H295R cell model.
Ullerås E; Ohlsson A; Oskarsson A
J Appl Toxicol; 2008 Nov; 28(8):1045-53. PubMed ID: 18626888
[TBL] [Abstract][Full Text] [Related]
30. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R.
Lichtenauer UD; Shapiro I; Geiger K; Quinkler M; Fassnacht M; Nitschke R; Rückauer KD; Beuschlein F
Endocrinology; 2008 Mar; 149(3):1314-22. PubMed ID: 18063677
[TBL] [Abstract][Full Text] [Related]
31. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice.
Martarelli D; Pompei P; Baldi C; Mazzoni G
Cancer Chemother Pharmacol; 2008 Apr; 61(5):809-17. PubMed ID: 17581752
[TBL] [Abstract][Full Text] [Related]
32. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
[TBL] [Abstract][Full Text] [Related]
33. Casein Kinase II: an attractive target for anti-cancer drug design.
Hanif IM; Hanif IM; Shazib MA; Ahmad KA; Pervaiz S
Int J Biochem Cell Biol; 2010 Oct; 42(10):1602-5. PubMed ID: 20558317
[TBL] [Abstract][Full Text] [Related]
34. Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro.
Schneider CC; Kartarius S; Montenarh M; Orzeszko A; Kazimierczuk Z
Bioorg Med Chem; 2012 Jul; 20(14):4390-6. PubMed ID: 22698781
[TBL] [Abstract][Full Text] [Related]
35. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
[TBL] [Abstract][Full Text] [Related]
36. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown.
Huang WC; Hsu RM; Chi LM; Leu YL; Chang YS; Yu JS
Cancer Lett; 2007 Apr; 248(1):137-46. PubMed ID: 16919867
[TBL] [Abstract][Full Text] [Related]
37. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.
Hou Z; Nakanishi I; Kinoshita T; Takei Y; Yasue M; Misu R; Suzuki Y; Nakamura S; Kure T; Ohno H; Murata K; Kitaura K; Hirasawa A; Tsujimoto G; Oishi S; Fujii N
J Med Chem; 2012 Mar; 55(6):2899-903. PubMed ID: 22339433
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells.
Apopa PL; He X; Ma Q
J Biochem Mol Toxicol; 2008 Feb; 22(1):63-76. PubMed ID: 18273910
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase CK2 subunits are positive regulators of AKT kinase.
Guerra B
Int J Oncol; 2006 Mar; 28(3):685-93. PubMed ID: 16465374
[TBL] [Abstract][Full Text] [Related]
40. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
